Potential for ALK's Grastek in U.S. depends on price, label: CEO
COPENHAGEN (Reuters) - The potential for Grastek, an oral allergy drug made by Denmark's ALK Abello and American partner Merck, will depend on the product's label and price in the United States, chief executive Jens Bager told Reuters on Friday.
The vaccine passed a review by the U.S. Food and Drug Administration on Thursday.
Jens Bager also told Reuters that he still expected the company to receive marketing authorization in the first quarter.
(Reporting by Shida Chayesteh)
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video